Amita Datta-Mannan is currently an Associate Vice President, Asset Team Leader, Clinical Team Leader and Clinical Pharmacologist in the Department of Exploratory Medicine and Pharmacology at Eli Lilly and Company. She earned her Bachelor of Science at McMaster University, Ontario, Canada, in 1998 and her PhD in Protein And Physical Chemistry from Brown University and Indiana University in 2003. Following her thesis work in cell biology, she went on to complete additional training in Clinical Pharmacology and Immunology at Harvard University before joining Eli Lilly as a pharmaceutical scientist. Dr. Datta-Mannan has ~20 years of experience leading cross-functional drug discovery and development teams in various program and portfolio leadership roles. Along these lines, Dr. Datta-Mannan has contributed to discovery and development of multiple medicinal modalities including monoclonal antibodies bispecific antibodies, antibody drug conjugates, small molecules, peptides and fusion proteins for autoimmunity, oncology, diabetes, migraine and musculoskeletal disorders. Dr. Datta-Mannan has key platform expertise in the areas of first in human trials, biopharmaceutical profiling and mechanisms influencing the disposition, biodistribution and metabolism of biologics following parenteral and oral delivery. She also developed the first surrogate chemokine receptor structures to dissect the structure-function relationship of receptor-ligand interactions for developing therapies directed at autoimmune disorders. Dr. Datta-Mannan has contributed to multiple patents, published over 50 peer reviewed manuscripts and abstracts, including invited scientific reviews and pharmaceutical industry whitepaper guidance documents for biologics, presented/chaired over 30 invited oral presentations and cross industry/regulatory consortia, and serves on the editorial/review board of several journals. She is passionate about enabling the progression of novel therapeutics and medicines to improve the quality of life globally.